Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company based in Cambridge, Massachusetts, that develops therapeutic products for immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. Its lead product candidate, VT-1953, is a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation in phase 2 clinical trials for bacterial conjunctivitis. The company also develops VT-1908, a topical eye drop that is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor for immunoinflammatory eye conditions, and VB-1953, which is in phase 2 for inflammatory acne. Additionally, it develops antifungal products using its molecular replacement therapy (MRT) platform and has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products.
USA